Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

mAbs

Volumn 5, Issue 1, 2013, Pages 22-33

  Klein, Christian ^a   Lammens, Alfred ^b   Schäfer, Wolfgang ^c   Georges, Guy ^c   Schwaiger, Manfred ^c   Mössner, Ekkehard ^a   Hopfner, Karl Peter ^b   Umaña, Pablo ^a   Niederfellner, Gerhard ^c  

^a Roche Glycart AG   (Switzerland)

^b UNIVERSITY OF MUNICH   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

GA101; Immunotherapy; Leukemia; Non Hodgkin lymphoma; Obinutuzumab; Ofatumumab; Rituximab; Structure; Type I; Type II

Indexed keywords

ALEMTUZUMAB; CD16 ANTIGEN; CD20 ANTIBODY; EPITOPE; FC RECEPTOR; FLUDARABINE; HU 8E4; IBRITUMOMAB TIUXETAN; LFB R603; OBINUTUZUMAB; OCARATUZUMAB; OCRELIZUMAB; OFATUMUMAB; PRO 131921; RHUMAB V114; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRU 015; UBLITUXIMAB; UNCLASSIFIED DRUG; VELTUZUMAB;

AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CARBOXY TERMINAL SEQUENCE; CELL CONTACT; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT FIXATION; DRUG BINDING; DRUG EFFICACY; EPITOPE MAPPING; FOLLICULAR LYMPHOMA; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYDROPHILICITY; HYDROPHOBICITY; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MEMBRANE BINDING; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; SITE DIRECTED MUTAGENESIS; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; CLINICAL TRIALS AS TOPIC; CRYSTALLOGRAPHY, X-RAY; EPITOPE MAPPING; EPITOPES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA;

EID: 84872875413     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.22771     Document Type: Article

References (85)

1. Cragg MS, Walshe CA, Ivanov A.O., Glennie MJ The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140-74; PMID:15564720; http://dx.doi.org/10.1159/000082102
2. Stashenko P, Nadler LM, Hardy R, Schlossman S F. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125:1678-85; PMID:6157744
3. Glennie MJ, French RR, Cragg M.S., Taylor R P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44:3823-37; PMID:17768100; http://dx.doi.org/10.1016/j.molimm.2007.06.151
4. Polyak MJ, Li H, Shariat N., Deans J P. CD20 homo-oligomers physically associate with the B cell antigen receptor. J Biol Chem 2008; 283:18545-52; PMID:18474602; http://dx.doi.org/10.1074/jbc.M800784200
5. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010; 70:1445-76; PMID:20614951; http://dx.doi.org/10.2165/11201110- 000000000-00000
6. Marcus R, Imrie K, Belch A., Cunningham D, Flores E, Catalano J., et al CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417-23; PMID:15494430; http://dx.doi.org/10.1182/blood-2004-08-3175
7. Forstpointner R, Dreyling M, Repp R., Hermann S, Hänel A, Metzner B., et al; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophospha-mide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104:3064-71; PMID:15284112; http://dx.doi.org/10.1182/blood- 2004-04-1323
8. Hiddemann W, Kneba M, Dreyling M., Schmitz N, Lengfelder E, Schmits R., et al Frontline therapy with rituximab added to the combination of cyclo-phosphamide, doxorubicin, vincristine, and predni-sone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725-32; PMID:16123223; http://dx.doi.org/10.1182/blood-2005-01-0016
9. van Oers M.H., Klasa R, Marcus R.E., Wolf M., Kimby E, Gascoyne RD, et al Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108:3295-301; PMID:16873669; http://dx.doi.org/10.1182/blood-2006- 05-021113
10. Herold M, Pasold R, Srock S., Neser S, Niederwieser D, Neubauer A., et al Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood 2004; 104:584
11. Fowler, NH. Role of maintenance rituximab (rituxan) therapy in the treatment of follicular lymphoma. P. T. 2011; 36:590-8
12. Salles G, Seymour J F, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377:42-51; PMID:21176949; http://dx.doi.org/10.1016/S0140-6736(10) 62175-7
13. van Oers M.H., Van Glabbeke M, Giurgea L, Klasa R., Marcus RE, Wolf M, et al Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28:2853-8; PMID:20439641; http://dx.doi.org/10.1200/JCO.2009.26.5827
14. Forstpointner R, Unterhalt M, Dreyling M., Böck HP, Repp R, Wandt H, et al.; German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood= 2006; 108:4003-8; PMID:16946304; http://dx.doi.org/10.1182/blood-2006-04-016725
15. Martinelli G, Schmitz S F, Utiger U, Cerny T., Hess U, Bassi S, et al Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480-4; PMID:20697092; http://dx.doi.org/10.1200/JCO.2010.28.4786
16. Vidal L, Gafter-Gvili A, Leibovici L., Shpilberg O. Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database Syst Rev 2009; CD006552; PMID:19370640
17. Eichhorst B, Dreyling M, Robak T., Montserrat E, Hallek M; ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22(Suppl 6):vi50-4; PMID:21908504; http://dx.doi.org/10.1093/annonc/mdr377
18. Tilly H, Dreyling M; ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5):v172-4; PMID:20555073; http://dx.doi.org/10.1093/annonc/mdq203
19. Dreyling M, Ghielmini M, Marcus R., Salles G, Vitolo U; ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22(Suppl 6):vi59-63; PMID:21908506; http://dx.doi.org/10.1093/annonc/mdr388
20. Lemery SJ, Zhang JZ, Rothmann M.D., Yang J., Earp JC, Zhao H, et al U.S. Clin Cancer Res 2010; 16:4331-8; PMID:20601446; http://dx.doi.org/10.1158/1078- 0432.CCR-10-0570
21. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S., Williams CD, Hellmann A, et al; Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1749-55; PMID:20194866; http://dx.doi.org/10.1200/JCO.2009.25. 3187
22. Illidge T, Morschhauser F. Radioimmunotherapy in follicular lymphoma. Best Pract Res Clin Haematol 2011; 24:279-93; PMID:21658624; http://dx.doi.org/10.1016/j.beha.2011.03.005
23. Lim SH, Beers SA, French R.R., Johnson PW, Glennie MJ, Cragg MS Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010; 95:135-43; PMID:19773256; http://dx.doi.org/10.3324/haematol.2008.001628
24. Chan HT, Hughes D, French R.R., Tutt AL, Walshe CA, Teeling JL, et al CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003; 63:5480-9; PMID:14500384
25. Cragg MS, Glennie MJ Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103:2738-43; PMID:14551143; http://dx.doi.org/10.1182/blood-2003-06-2031
26. Cragg MS, Morgan SM, Chan H.T., Morgan B P, Filatov AV, Johnson P W, et al Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101:1045-52; PMID:12393541; http://dx.doi.org/10.1182/ blood-2002-06-1761
27. Mössner E., Brünker P, Moser S., Püntener U, Schmidt C., Herter S, et al Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393-402; PMID:20194898; http://dx.doi.org/10.1182/blood-2009-06-225979
28. Alduaij W, Ivanov A, Honeychurch J., Cheadle EJ, Potluri S, Lim SH, et al Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011; 117:4519-29; PMID:21378274; http://dx.doi.org/10.1182/blood-2010-07-296913
29. Niederfellner G, Lammens A, Mundigl O., Georges GJ, Schaefer W, Schwaiger M, et al Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011; 118:358-67; PMID:21444918; http://dx.doi.org/10.1182/blood-2010-09- 305847
30. MabThera SmPC. June 2012. Available at: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000165/WC500025821.pdf. Accessed October 2012
31. Clinical trials information is available at: http://www.clinicaltrials. gov. Accessed October 2012
32. Deans J.P., Robbins SM, Polyak M.J., Savage JA Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 1998; 273:344-8; PMID:9417086; http://dx.doi.org/10.1074/jbc.273.1.344
33. Polyak MJ, Deans J P. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002; 99:3256-62; PMID:11964291; http://dx.doi.org/10.1182/blood.V99.9.3256
34. Beers SA, Chan CH, James S, French R.R., Attfield KE, Brennan CM, et al Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008; 112:4170-7; PMID:18583569; http://dx.doi.org/10.1182/ blood-2008-04-149161
35. Teeling JL, French RR, Cragg M.S., van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104:1793-800; PMID:15172969; http://dx.doi.org/10.1182/blood-2004-01-0039
36. Cragg MS. CD20 antibodies: doing the time warp. Blood 2011; 118:219-20; PMID:21757627; http://dx.doi.org/10.1182/blood-2011-04-346700
37. Ivanov A, Beers SA, Walshe C.A., Honeychurch J., Alduaij W, Cox KL, et al Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009; 119:2143-59; PMID:19620786
38. Jak M, van Bochove G, Klein C, Umana P., Eldering E, Van Oers MHJ. CD40 stimulation sensitizes CLL cells to CD20-triggered cell death by rituximab and GA101 via a different mechanism. Blood 2011; 118:5178-88
39. Honeychurch J, Alduaij W, Azizyan M., Cheadle EJ, Pelicano H, Ivanov A, et al Antibody-induced non-apoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 2012; 119:3523-33; PMID:22354003; http://dx.doi.org/10.1182/blood-2011-12- 395541
40. Cartron G, Dacheux L, Salles G., Solal-Celigny P, Bardos P, Colombat P., et al Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8; PMID:11806974; http://dx.doi.org/10.1182/blood.V99.3.754
41. Cartron G, Watier H, Golay J., Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104:2635-42; PMID:15226177; http://dx.doi.org/10.1182/blood-2004-03-1110
42. Koene HR, Kleijer M, Algra J., Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gam-maRIIIa-48L/R/H phenotype. Blood 1997; 90:1109-14; PMID:9242542
43. Ferrara C, Stuart F, Sondermann P., Brünker P, Umaña P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006; 281:5032-6; PMID:16330541; http://dx.doi.org/10.1074/jbc.M510171200
44. Bowles JA, Wang SY, Link B.K., Allan B., Beuerlein G, Campbell MA, et al Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006; 108:2648-54; PMID:16825493; http://dx.doi.org/10.1182/blood-2006-04-020057
45. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-7; PMID:12975461; http://dx.doi.org/10. 1200/JCO.2003.05.013
46. Beers SA, French RR, Chan H.T., Lim SH, Jarrett TC, Vidal RM, et al Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010; 115:5191-201; PMID:20223920; http://dx.doi.org/10.1182/blood-2010-01-263533
47. Lim SH, Vaughan AT, Ashton-Key M, Williams E.L., Dixon SV, Chan HT, et al Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011; 118:2530-40; PMID:21768293; http://dx.doi.org/10.1182/blood-2011-01-330357
48. Teeling JL, Mackus WJ, Wiegman L.J., van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177:362-71; PMID:16785532
49. Binder M, Otto F, Mertelsmann R., Veelken H, Trepel M. The epitope recognized by rituximab. Blood 2006; 108:1975-8; PMID:16705086; http://dx.doi.org/10.1182/blood-2006-04-014639
50. Du J, Wang H, Zhong C., Peng B, Zhang M, Li B., et al Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem 2007; 282:15073-80; PMID:17395584; http://dx.doi.org/10.1074/jbc.M701654200
51. Du J, Wang H, Zhong C., Peng B, Zhang M, Li B., et al Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide. Mol Immunol 2008; 45:2861-8; PMID:18346788; http://dx.doi.org/10.1016/j.molimm.2008.01.034
52. Du J, Yang H, Guo Y., Ding J. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol 2009; 46:2419-23; PMID:19427037; http://dx.doi.org/10. 1016/j.molimm.2009.04.009
53. Perosa F, Favoino E, Caragnano M.A., Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 2006; 107:1070-7; PMID:16223774; http://dx.doi.org/10.1182/blood-2005-04-1769
54. Perosa F, Favoino E, Vicenti C., Guarnera A, Racanelli V, De Pinto V, et al Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes. J Immunol 2009; 182:416-23; PMID:19109173
55. Ernst JA, Li H, Kim H.S., Nakamura GR, Yansura DG, Vandlen RL Isolation and characterization of the B-cell marker CD20. Biochemistry 2005; 44:15150-8; PMID:16285718; http://dx.doi.org/10.1021/bi0511078
56. Li B, Zhao L, Guo H., Wang C, Zhang X, Wu L., et al Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009; 114:5007-15; PMID:19828699; http://dx.doi.org/10. 1182/blood-2009-06-225474
57. Johnson NA, Leach S, Woolcock B., deLeeuw RJ, Bashashati A, Sehn LH, et al CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica 2009; 94:423-7; PMID:19211644; http://dx.doi.org/10.3324/haematol. 2008.001024
58. Morschhauser F, Leonard J P, Fayad L, Coiffier B., Petillon MO, Coleman M, et al Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol 2009; 27:3346-53; PMID:19451441; http://dx.doi.org/10.1200/JCO.2008.19.9117
59. Goldenberg DM, Rossi EA, Stein R, Cardillo T.M., Czuczman MS, Hernandez-Ilizaliturri FJ, et al Properties and structure-function relationships of vel-tuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009; 113:1062-70; PMID:18941114; http://dx.doi.org/10.1182/blood-2008-07-168146
60. Forero-Torres A., de Vos S, Pohlman BL, Pashkevich M, Cronier D.M., Dang NH, et al Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FCγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 2012; 18:1395-403; PMID:22223529; http://dx.doi.org/10.1158/1078-0432.CCR-11-0850
61. Gordon LI, Molina A, Witzig T., Emmanouilides C, Raubtischek A, Darif M., et al Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103:4429-31; PMID:15016644; http://dx.doi.org/10.1182/blood-2003-11-3883
62. Witzig TE, White CA, Wiseman G.A., Gordon LI, Emmanouilides C, Raubitschek A, et al Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3793-803; PMID:10577851
63. Witzig TE, Gordon LI, Cabanillas F, Czuczman M.S., Emmanouilides C., Joyce R, et al Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-63; PMID:12011122; http://dx.doi.org/10.1200/JCO.2002.11.076
64. Wiseman GA, Gordon LI, Multani P.S., Witzig TE, Spies S, Bartlett NL, et al Ibritumomab tiuxetan radio-immunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336-42; PMID:12036859; http://dx.doi.org/10. 1182/blood.V99.12.4336
65. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P., Tilly H, et al Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26:5156-64; PMID:18854568; http://dx.doi.org/10.1200/JCO.2008.17.2015
66. Hainsworth JD, Spigel DR, Markus T.M., Shipley D., Thompson D, Rotman R, et al Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 2009; 9:223-8; PMID:19525191; http://dx.doi.org/10.3816/CLM.2009.n.044
67. Morschhauser F, Marlton P, Vitolo U., Lindén O, Seymour J F, Crump M, et al Results of a phase I/ II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010; 21:1870-6; PMID:20157180; http://dx.doi.org/10.1093/annonc/mdq027
68. Sikder MA, Friedberg JW Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Curr Hematol Malig Rep 2008; 3:187-93; PMID:20425465; http://dx.doi.org/10.1007/s11899-008-0027-5
69. Shields RL, Namenuk AK, Hong K, Meng Y.G., Rae J., Briggs J, et al High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591-604; PMID:11096108; http://dx.doi.org/10.1074/jbc.M009483200
70. + indolent NHL: Correlation between clinical responses and AUC pharmacokinetics. Blood 2009; 114:3742
71. Hayden-Ledbetter M.S., Cerveny CG, Espling E, Brady W.A., Grosmaire LS, Tan P, et al CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res 2009; 15:2739-46; PMID:19351771; http://dx.doi.org/10.1158/1078-0432.CCR-08-1694
72. Czuczman MS, Fayad L, Delwail V., Cartron G, Jacobsen E, Kuliczkowski K., et al; 405 Study Investigators. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 2012; 119:3698-704; PMID:22389254; http://dx.doi.org/10.1182/blood-2011-09-378323
73. Czuczman MS, Hess G, Gadeberg O.V., Pedersen LM, Goldstein N, Gupta I, et al; 409 Study Investigators. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol 2012; 157:438-45; PMID:22409295; http://dx.doi.org/10.1111/j.1365-2141.2012.09086.x
74. Hagenbeek A, Plesner T, Johnson P., Pedersen L, Walewski J, Hellman A., et al HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma. Blood 2005; 106:Abstract 4760
75. Uchiyama S, Suzuki Y, Otake K., Yokoyama M, Ohta M, Aikawa S., et al Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. Cancer Sci 2010; 101:201-9; PMID:19930155; http://dx.doi.org/10. 1111/j.1349-7006.2009.01392.x
76. Engelberts P, Beurskens F, Mackus W., Bakker J, Vink T, Tiebout A., et al Ofatumuab targets a conformational membrane-proximal epitope which contains amino acids located in the small and large loops of CD20. Haematologica 2010; 95:46
77. Beum P.V., Lindorfer MA, Beurskens F, Stukenberg P T, Lokhorst HM, Pawluczkowycz A.W., et al Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008; 181:822-32; PMID:18566448
78. Herter S, Waldhauer I, Otz T., Herting F, Lang S, Nicolini V., et al Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101vs. The Type I CD20 Antibodies Rituximab and Ofatumumab. Blood 2010; 116:3925
79. Wu L, Wang C, Zhang D., Zhang X, Qian W, Zhao L., et al Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma. Cancer Lett 2010; 292:208-14; PMID:20056316; http://dx.doi.org/10. 1016/j.can-let.2009.12.004
80. Baritaki S, Militello L, Malaponte G., Spandidos DA, Salcedo M, Bonavida B. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/ RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. Int J Oncol 2011; 38:1683-94; PMID:21455568
81. Kaminski MS, Zelenetz AD, Press O.W., Saleh M., Leonard J, Fehrenbacher L, et al Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19:3918-28; PMID:11579112
82. Davis TA, Kaminski MS, Leonard J P, Hsu FJ, Wilkinson M, Zelenetz A., et al The radioisotope contributes significantly to the activity of radioim-munotherapy. Clin Cancer Res 2004; 10:7792-8; PMID:15585610; http://dx.doi.org/10.1158/1078-0432.CCR-04-0756
83. Nishida M, Usuda S, Okabe M., Miyakoda H, Komatsu M, Hanaoka H., et al Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). Int J Oncol 2007; 31:29-40; PMID:17549402
84. Stein R, Qu Z, Chen S., Rosario A, Shi V, Hayes M., et al Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004; 10:2868-78; PMID:15102696; http://dx.doi.org/10.1158/1078-0432.CCR-03-0493
85. Forero-Torres A., de Vos S, Pohlman BL, Pashkevich M, Cronier D.M., Dang NH, et al Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FCγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 2012; 18:1395-403; PMID:22223529; http://dx.doi.org/10.1158/1078-0432.CCR-11-0850